+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia

Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia

Blood 64(5): 1085-1093

A phase I clinical trial was initiated to treat patients with stage IV B-derived chronic lymphocytic leukemia (CLL) with the IgG2a murine monoclonal antibody T101. This antibody binds to a 65,000-mol wt (T65) antigen found on normal T lymphocytes, malignant T lymphocytes, and B-derived CLL cells. All of the patients had a histologically confirmed diagnosis of advanced B-derived CLL and were refractory to standard therapy, and more than 50% of their leukemia cells reacted with the T101 antibody in vitro. The patients received T101 antibody two times per week, over two to 50 hours by intravenous administration in 100 mL of normal saline containing 5% human albumin. Twelve patients were treated with a fixed dosage of 1, 10, 50, or 100 mg, and one patient was treated with 140 mg of antibody. It was demonstrated that patients given two-hour infusions of 50 mg developed pulmonary toxicity, with shortness of breath and chest tightness. This toxicity was eliminated when infusions of 50 or 100 mg of T101 were prolonged to 50 hours. All dose levels caused a rapid but transient decrease in circulating leukemia cell counts. In vivo binding to circulating and bone marrow leukemia cells was demonstrated at all dose levels with increased binding at higher dosages. Antimurine antibody responses were not demonstrated in any patients at any time during treatment. Circulating free murine antibody was demonstrated in the serum of only the two patients treated with 100 mg of antibody as a 50-hour infusion and the patient treated with 140 mg of antibody over 30 hours. Antigenic modulation was demonstrated in patients treated at all dose levels but was particularly apparent in patients treated with prolonged infusions of 50 and 100 mg of antibody. We were also able to demonstrate antigenic modulation in lymph node cells, which strongly suggests in vivo labeling of these cells. Overall, T101 antibody alone appears to have a very limited therapeutic value for patients with CLL. The observations of in vivo labeling of tumor cells, antigenic modulation, antibody pharmacokinetics, toxicity, and antimurine antibody formation may be used in the future for more effective therapy when drugs or toxins are conjugated to the antibody.

(PDF 0-2 workdays service: $29.90)

Accession: 005314850

Download citation: RISBibTeXText

PMID: 6333257

Related references

Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 59(5): 1036-1045, 1982

Monoclonal antibody therapy of chronic lymphocytic leukemia. Journal of Clinical Oncology 21(9): 1874-1881, 2003

Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunology, ImmunoTherapy 55(2): 188-196, 2005

Update on monoclonal antibody therapy in chronic lymphocytic leukemia. Clinical Advances in Hematology & Oncology 2(2): 107-113, 2005

Severe side effects in patients with B-cell chronic lymphocytic leukemia and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab. Blood 92(10 SUPPL 1 PART 1-2): 285B, Nov 15, 1998

Current status of monoclonal antibody therapy for chronic lymphocytic leukemia. Oncology 17(2): 253-62; Discussion 264, 267, Passim, 2003

Severe side effects and acute tumor lysis in patients with B-cell chronic lymphocytic leukemia treated with an anti-CD20 monoclonal antibody. Annals of Hematology 77(SUPPL 2): S95, 1998

Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clinical Lymphoma, Myeloma & Leukemia 10(5): 361-368, 2011

A monoclonal antibody detecting a 39,000 m.w. molecule that is present on B lymphocytes and chronic lymphocytic leukemia cells but is rare on acute lymphocytic leukemia blasts. Journal of Immunology 131(6): 3064-3072, 1983

Cytotoxic monoclonal antibody jd 118 potential for therapy of chronic lymphocytic leukemia cll and non hodgkins lymphoma nhl. Proceedings of the American Association for Cancer Research Annual Meeting 31: 288, 1990

Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. Journal of Clinical Oncology 2(8): 881-891, 1984

T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. Journal of Immunology 133(3): 1641-1648, 1984

Radioimmunotherapy treatment of patients with chronic lymphocytic leukemia using iodine 131 labeled murine monoclonal antibody t101. Journal of Nuclear Medicine 29(5 SUPPL): 901-902, 1988

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 51(2): 228-235, 2010

Phase I Study of Combination Rituximab and Apolizumab Monoclonal Antibody Therapy in Previously Treated B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Blood 100(11): Abstract No 1389, November 16, 2002